JP2010530438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530438A5 JP2010530438A5 JP2010513369A JP2010513369A JP2010530438A5 JP 2010530438 A5 JP2010530438 A5 JP 2010530438A5 JP 2010513369 A JP2010513369 A JP 2010513369A JP 2010513369 A JP2010513369 A JP 2010513369A JP 2010530438 A5 JP2010530438 A5 JP 2010530438A5
- Authority
- JP
- Japan
- Prior art keywords
- quinazoline
- carboxamide
- amino
- dichloro
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- -1 O (CR 2 ) q R 4 Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 102000000503 Collagen Type II Human genes 0.000 claims 2
- 108010041390 Collagen Type II Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000009386 Experimental Arthritis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000021510 thyroid gland disease Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- UINCOVQQBKMABV-UHFFFAOYSA-N 4-[(2,4-dimethoxyphenyl)methylamino]-n-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=C(C(=O)NC=3C(=CC=C(NC(=O)C=4C=C(C=CC=4)C(F)(F)F)C=3)C)C=CC=C12 UINCOVQQBKMABV-UHFFFAOYSA-N 0.000 claims 1
- AVPZRQOWJMIECH-UHFFFAOYSA-N 4-amino-n-(2,6-dichloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl AVPZRQOWJMIECH-UHFFFAOYSA-N 0.000 claims 1
- HIMKYXREQLEWMQ-UHFFFAOYSA-N 4-amino-n-(2,6-dichloro-3-cyano-5-methoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(C#N)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl HIMKYXREQLEWMQ-UHFFFAOYSA-N 0.000 claims 1
- WSTJETSUIZMOIF-UHFFFAOYSA-N 4-amino-n-(2,6-difluoro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(F)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1F WSTJETSUIZMOIF-UHFFFAOYSA-N 0.000 claims 1
- LTLHWUBPWLYYSN-UHFFFAOYSA-N 4-amino-n-(2-bromo-6-chloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Br)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl LTLHWUBPWLYYSN-UHFFFAOYSA-N 0.000 claims 1
- SPWTVSNTAGFMHW-UHFFFAOYSA-N 4-amino-n-(2-chloro-3,5-dimethoxy-6-methylphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1C SPWTVSNTAGFMHW-UHFFFAOYSA-N 0.000 claims 1
- CHOJUHJYFAYISK-UHFFFAOYSA-N 4-amino-n-(2-chloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=CC(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl CHOJUHJYFAYISK-UHFFFAOYSA-N 0.000 claims 1
- CGAVPBNRRTURCI-UHFFFAOYSA-N 4-amino-n-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1F CGAVPBNRRTURCI-UHFFFAOYSA-N 0.000 claims 1
- BRPQFUCXCWSPCI-UHFFFAOYSA-N 4-amino-n-(2-methylnaphthalen-1-yl)quinazoline-8-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CC=CC4=CC=C3C)=CC=CC2=C1N BRPQFUCXCWSPCI-UHFFFAOYSA-N 0.000 claims 1
- LQDXGMBFIYCGJQ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylcarbamoyl)-5-ethoxyphenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OCC)=CC=1C(=O)NC1CC1 LQDXGMBFIYCGJQ-UHFFFAOYSA-N 0.000 claims 1
- OVAUJQPLCIGAFU-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylcarbamoyl)-5-fluorophenyl]quinazoline-8-carboxamide Chemical compound C1=CC=C2C(N)=NC=NC2=C1C(=O)NC(C=1Cl)=C(Cl)C(F)=CC=1C(=O)NC1CC1 OVAUJQPLCIGAFU-UHFFFAOYSA-N 0.000 claims 1
- OUKLJJSDBADJHE-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1CC1 OUKLJJSDBADJHE-UHFFFAOYSA-N 0.000 claims 1
- OQXGBXHTPMAGKI-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(cyclopropylmethylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NCC1CC1 OQXGBXHTPMAGKI-UHFFFAOYSA-N 0.000 claims 1
- JDAPUBNMZXUCDJ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(dimethylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound COC1=CC(C(=O)N(C)C)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl JDAPUBNMZXUCDJ-UHFFFAOYSA-N 0.000 claims 1
- RATUYKSQHCLFTJ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethoxycarbamoyl)-5-fluorophenyl]quinazoline-8-carboxamide Chemical compound CCONC(=O)C1=CC(F)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl RATUYKSQHCLFTJ-UHFFFAOYSA-N 0.000 claims 1
- SWHJPMMJNKGTBR-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethoxycarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound CCONC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl SWHJPMMJNKGTBR-UHFFFAOYSA-N 0.000 claims 1
- GBOXLCTWINDHBP-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethylcarbamoyl)-5-fluorophenyl]quinazoline-8-carboxamide Chemical compound CCNC(=O)C1=CC(F)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl GBOXLCTWINDHBP-UHFFFAOYSA-N 0.000 claims 1
- IBWOCLVQLGBCMP-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-(ethylcarbamoyl)-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound CCNC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl IBWOCLVQLGBCMP-UHFFFAOYSA-N 0.000 claims 1
- VQZXLDFQVUWCPY-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-ethoxy-5-(ethoxycarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound CCONC(=O)C1=CC(OCC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl VQZXLDFQVUWCPY-UHFFFAOYSA-N 0.000 claims 1
- KQQUOLDEUSAZJQ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-ethoxy-5-(ethylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound CCNC(=O)C1=CC(OCC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl KQQUOLDEUSAZJQ-UHFFFAOYSA-N 0.000 claims 1
- FNWPSDWHVXMUPD-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(phenylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1=CC=CC=C1 FNWPSDWHVXMUPD-UHFFFAOYSA-N 0.000 claims 1
- MVHVNNPMNKVHJK-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(propylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound CCCNC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl MVHVNNPMNKVHJK-UHFFFAOYSA-N 0.000 claims 1
- LZPIJUSWLNETDB-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(pyridin-2-ylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1=CC=CC=N1 LZPIJUSWLNETDB-UHFFFAOYSA-N 0.000 claims 1
- XSIVHMVKGDOVQZ-UHFFFAOYSA-N 4-amino-n-[2,6-dichloro-3-methoxy-5-(pyridin-3-ylcarbamoyl)phenyl]quinazoline-8-carboxamide Chemical compound ClC=1C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C(Cl)C(OC)=CC=1C(=O)NC1=CC=CN=C1 XSIVHMVKGDOVQZ-UHFFFAOYSA-N 0.000 claims 1
- KRGCJHVGTOJSMD-UHFFFAOYSA-N 4-amino-n-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]quinazoline-8-carboxamide Chemical compound C1=C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 KRGCJHVGTOJSMD-UHFFFAOYSA-N 0.000 claims 1
- JPIDPKIRDNEUIY-UHFFFAOYSA-N 4-amino-n-[3-(butylcarbamoyl)-2,6-dichloro-5-methoxyphenyl]quinazoline-8-carboxamide Chemical compound CCCCNC(=O)C1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(N)=C3C=CC=2)=C1Cl JPIDPKIRDNEUIY-UHFFFAOYSA-N 0.000 claims 1
- SKPWWMGEZMVQLO-UHFFFAOYSA-N 4-chloro-n-(2,6-dichloro-3,5-dimethoxyphenyl)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(Cl)=C3C=CC=2)=C1Cl SKPWWMGEZMVQLO-UHFFFAOYSA-N 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- OUYJFMALBOPXOP-UHFFFAOYSA-N n-(2,6-dichloro-3,5-dimethoxyphenyl)-4-(pyridin-2-ylamino)quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(NC=4N=CC=CC=4)=C3C=CC=2)=C1Cl OUYJFMALBOPXOP-UHFFFAOYSA-N 0.000 claims 1
- YVRUTCUMEVXMAK-UHFFFAOYSA-N n-(2,6-dichloro-3,5-dimethoxyphenyl)-4-[[5-(morpholin-4-ylmethyl)pyridin-2-yl]amino]quinazoline-8-carboxamide Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)C=2C3=NC=NC(NC=4N=CC(CN5CCOCC5)=CC=4)=C3C=CC=2)=C1Cl YVRUTCUMEVXMAK-UHFFFAOYSA-N 0.000 claims 1
- FABFTFOSZVAQLN-UHFFFAOYSA-N n-[3-[(1-ethylpyrrolidin-2-yl)methoxy]-5-(trifluoromethyl)phenyl]-4-methoxyquinazoline-8-carboxamide Chemical compound CCN1CCCC1COC1=CC(NC(=O)C=2C3=NC=NC(OC)=C3C=CC=2)=CC(C(F)(F)F)=C1 FABFTFOSZVAQLN-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 0 C*=C(CN(C)*)C(N)=C(*)C(C)=NC=C Chemical compound C*=C(CN(C)*)C(N)=C(*)C(C)=NC=C 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94541007P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/067290 WO2008157575A1 (en) | 2007-06-21 | 2008-06-18 | Protein kinase inhibitors and methods for using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530438A JP2010530438A (ja) | 2010-09-09 |
| JP2010530438A5 true JP2010530438A5 (enExample) | 2011-08-04 |
Family
ID=39682516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513369A Pending JP2010530438A (ja) | 2007-06-21 | 2008-06-18 | プロテインキナーゼ阻害剤およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110053932A1 (enExample) |
| EP (1) | EP2170842A1 (enExample) |
| JP (1) | JP2010530438A (enExample) |
| KR (1) | KR20100035635A (enExample) |
| CN (1) | CN101687821A (enExample) |
| AU (1) | AU2008265843B2 (enExample) |
| BR (1) | BRPI0813216A2 (enExample) |
| CA (1) | CA2691100A1 (enExample) |
| EA (1) | EA201000003A1 (enExample) |
| MX (1) | MX2009013781A (enExample) |
| WO (1) | WO2008157575A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579355A (en) | 2007-02-01 | 2012-03-30 | Resverlogix Corp | 2-(Aryl)-4-oxo-quinazoline derivatives |
| JP2011513329A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体 |
| EP2265610B1 (en) * | 2008-02-29 | 2012-12-12 | Array Biopharma, Inc. | Pyrazole [3, 4-b]pyridine raf inhibitors |
| AR070535A1 (es) * | 2008-02-29 | 2010-04-14 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para usarlos |
| US20110003859A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| US8822500B2 (en) * | 2008-03-19 | 2014-09-02 | Chembridge Corporation | Tyrosine kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP3210609A1 (en) | 2008-05-21 | 2017-08-30 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| CN105859639A (zh) | 2009-03-18 | 2016-08-17 | 雷斯韦洛吉克斯公司 | 新的抗炎剂 |
| JP5813626B2 (ja) | 2009-04-22 | 2015-11-17 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
| CA2784807C (en) * | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011147764A1 (en) | 2010-05-28 | 2011-12-01 | N.V. Organon | Thieno (2, 3b) pyrazine compounds as b - raf inhibitors |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| EP3429307B1 (en) | 2011-08-10 | 2022-06-15 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| US10321419B2 (en) | 2011-08-10 | 2019-06-11 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| KR101967721B1 (ko) | 2011-08-10 | 2019-04-10 | 삼성전자 주식회사 | 무선 통신 시스템에서 확장 접속 차단 적용 방법 및 장치 |
| KR102247818B1 (ko) | 2011-08-10 | 2021-05-04 | 삼성전자 주식회사 | 이동통신 시스템에서 복수의 캐리어를 이용해서 데이터를 전송하는 방법 및 장치 |
| WO2013051853A1 (en) | 2011-10-05 | 2013-04-11 | Samsung Electronics Co., Ltd. | Method and apparatus for selecting neighbor cells in mobile communication system |
| EP2765806B1 (en) | 2011-10-05 | 2020-09-23 | Samsung Electronics Co., Ltd. | Method and apparatus for reselecting a cell in heterogeneous networks in a wireless communication system |
| EP2768158B1 (en) | 2011-10-10 | 2018-09-05 | Samsung Electronics Co., Ltd. | Method and device for receiving a multimedia broadcast multicast service in a mobile communication system |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| SI2906531T1 (en) * | 2012-10-15 | 2018-03-30 | Resverlogix Corp. | Compounds useful for the synthesis of benzamide compounds |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| SMT202400187T1 (it) | 2014-11-06 | 2024-07-09 | Bial R&D Investments S A | Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| EP3268007B1 (en) | 2015-03-13 | 2022-11-09 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| US9890163B2 (en) | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
| EP3440081A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| SG11201808830YA (en) | 2016-04-06 | 2018-11-29 | Lysosomal Therapeutics Inc | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| WO2017192929A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN112979615B (zh) * | 2019-12-17 | 2024-08-09 | 上海医药集团股份有限公司 | 一种喹唑啉脲类化合物、其制备方法、制备中间体、药物组合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7031500A (en) * | 1999-09-23 | 2001-04-24 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| CA2412592A1 (en) * | 2000-06-28 | 2002-01-03 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| AU2003270199A1 (en) * | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| KR20070011501A (ko) * | 2004-04-28 | 2007-01-24 | 애로우 쎄라퓨틱스 리미티드 | 항바이러스제로서 유용한 모르폴리닐아닐리노퀴나졸린유도체 |
-
2008
- 2008-06-18 BR BRPI0813216-0A2A patent/BRPI0813216A2/pt not_active IP Right Cessation
- 2008-06-18 AU AU2008265843A patent/AU2008265843B2/en not_active Expired - Fee Related
- 2008-06-18 CA CA2691100A patent/CA2691100A1/en not_active Abandoned
- 2008-06-18 JP JP2010513369A patent/JP2010530438A/ja active Pending
- 2008-06-18 WO PCT/US2008/067290 patent/WO2008157575A1/en not_active Ceased
- 2008-06-18 US US12/665,894 patent/US20110053932A1/en not_active Abandoned
- 2008-06-18 KR KR1020097026460A patent/KR20100035635A/ko not_active Withdrawn
- 2008-06-18 EP EP08771318A patent/EP2170842A1/en not_active Withdrawn
- 2008-06-18 MX MX2009013781A patent/MX2009013781A/es active IP Right Grant
- 2008-06-18 EA EA201000003A patent/EA201000003A1/ru unknown
- 2008-06-18 CN CN200880021088A patent/CN101687821A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530438A5 (enExample) | ||
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| JP2010510242A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| RU2012136451A (ru) | Композиции и способы улучшения активности протеасомы | |
| JP2011514894A5 (enExample) | ||
| JP2010540452A5 (enExample) | ||
| JP2010530432A5 (enExample) | ||
| RU2008141434A (ru) | Пиразолы как 11-бета-hsd-1 | |
| JP2010538076A5 (enExample) | ||
| JP2010506918A5 (enExample) | ||
| RU2009119290A (ru) | Производные гидантоина, используемые в качестве ингибиторов ммр | |
| JP2007519754A5 (enExample) | ||
| JP2007535551A5 (enExample) | ||
| RU2010115574A (ru) | Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток | |
| JP6319436B2 (ja) | ２−アシルアミノチアゾール誘導体またはその塩 | |
| ME02696B (me) | MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI | |
| RU2008108984A (ru) | Терапевтический агент от диабета | |
| NZ601408A (en) | Novel 3-hydroxy-5-arylisothiazole derivative | |
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| JP2013503901A5 (enExample) | ||
| RU2012129737A (ru) | Замещенные бензамидные производные | |
| RU2015144653A (ru) | Противовирусные соединения и их применения | |
| JPWO2021000935A5 (enExample) | ||
| JP2019507179A5 (enExample) |